Center for Molecular Medicine Cologne

Prof. Dr. med. Hinrich Abken - Curriculum Vitae

Education and professional career

since 2012: Member of the Scientific Advisory Board of the Federal Ministry of Education and Research (BMBF), Berlin Member of the Advisory Board of biotech companies in Europe and the US
2005 - 2013: Co-founder and member of the Managing Board of the FP6 EU Consortium ‘ATTACK’ (adoptive engineered T-cell targeting to activate cancer killing) and FP7 ‘ATTRACT’ (Advanced Teaching and Training for Adoptive Cell Therapy)
2004 - 2008: Member of the Helmholtz Institute for Biohybrid Technology (IBHT) in Aachen
2000: Co-Founder of ‘AbGen’ (now ‘Curacyte’), a biotechnology start-up company in München
1997 - 2017: Weiterbildungsermächtigung ‘Biochemistry’ (Advanced Training Authorization for the Board Certification)
1996: Board certification in ‘Biochemistry’
since 1994: Member of the Center for Molecular Medicine Cologne (CMMC)
since 1993: Full Professor at the Clinic I for Internal Medicine, Medical Faculty, University of Cologne
1993: Habilitation and lecture qualification for ‘Genetics and Immunology’, Faculty of Math. and Nat. Sciences of the University of Bonn
1987 - 1993: Lecturer (Hochschulassistent C1), Genetics Institute, Department of Molecular Genetics (Prof. K. Willecke), Faculty of Math. and Nat. Sciences, University of Bonn
1983 - 1987: Research assistant, Institute for Cell Biology (Prof. M.F. Rajewsky), Medical School, University Essen
1980 - 1983: Medical Doctorate at the Department of Molecular Biology, University Essen

Selected publications

Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel D, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C and Endres S. Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. J Natl Cancer Inst 107. 2014, 364 - doi: 10.1093/jnci/dju364.

Krebs K, Böttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jäger C, Schmitt E, Bohne F, Aichler M, Uckert W, Abken H, Heikenwalder M, Knolle P, Protzer U. T cells expressing a chimeric antigen receptor that binds Hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145. 2013, 456 - 465, doi: 10.1053/j.gastro.2013.04.047.

Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA, Abken H. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing auto-immune colitis in mice. Gastroenterology 143. 2012, 1095 – 1107, doi: 10.1053/j. gastro.2012.06.037.

Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143. 2012, 1375 - 1384, doi: 10.1053/j.gastro.2012.07.017.

Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71. 2011, 5697 - 5706.

Schmidt P, Kopecky C, Hombach A, Zingrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA. 2011, 108, 2474 – 2479, Faculty of 1000: "Recommended".

Stewart-Jones G, Wadle A, Hombach A, Shenderow E, Held G, Fischer E, Kleber S, Stenner F, Bauer S, McMichael A, Knuth A, Abken H, Hombach A, Cerundolo V, Jones E, Renner C. Rational development of high affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA. 2009, 106, 5784 – 5788.

Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling, R, Blankenstein T, Abken H, Charo J. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA. 2008, 105, 17481 – 17486.

Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kürschner T, Schulze A, Urban S, Krönke M, Abken H, Protzer U. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology. 2008, 134, 239 – 247.

Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermöhlen O, Heimlich G, Abken H, Krönke M. XIAP targeting sensitizes Hodgkin´s lymphoma cells for cytolytic T cell attack. Blood. 2006, 108, 3434 – 3440.